US · Healthcare · Drug Manufacturers - General
EPS came in at 1.36 against a street estimate of 1.27 — a beat of 7.1%.
Analysts rate GlaxoSmithKline PLC ADR a hold (1 buy, 5 hold, 2 sell out of 8) with an average price target of $58.08.
| Fund | Stake |
|---|---|
| FMR Inc | 3.38% |
| Dodge & Cox | 2.93% |
| Fisher Asset Management, LLC | 1.72% |
| PRIMECAP Management Company | 1.26% |
| Acadian Asset Management LLC | 0.59% |
| Wellington Management Company LLP | 0.58% |
| Morgan Stanley - Brokerage Accounts | 0.55% |
| The Goldman Sachs Group Inc | 0.48% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.45 / share ex-date Aug 14, 2026 · pay Oct 8, 2026 | 2026-08-14 |
| Dividend | $0.46 / share ex-date May 15, 2026 · pay Jul 9, 2026 | 2026-05-15 |
| Dividend | $0.49 / share ex-date Feb 20, 2026 · pay Apr 9, 2026 | 2026-02-20 |
| Dividend | $0.42 / share ex-date Nov 14, 2025 · pay Jan 8, 2026 | 2025-11-14 |
| Dividend | $0.43 / share ex-date Aug 15, 2025 · pay Oct 9, 2025 | 2025-08-15 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for GlaxoSmithKline PLC ADR — free to start.
Google PlayApp StoreData updated 2026-08-05.